Skip to main content
SpringerLink
Log in
Book cover

Focal Controlled Drug Delivery pp 387–403Cite as

Drug-Eluting Stents

  • Chapter
  • First Online:

Part of the book series: Advances in Delivery Science and Technology ((ADST))

Abstract

Advances in the field of stents have revolutionised the treatment of coronary artery diseases. To provide effective treatment for coronary artery disease, a stent has to be deliverable and flexible, cause minimal trauma to the vessel wall, cause minimal inflammatory reaction, endothelialise well, provide scaffolding for the vessel, and finally promote vessel healing and remodelling. Bare-metal stents (BMS) have been commonly used to treat symptomatic coronary artery disease during the past two decades, but long-term results have shown problems of in-stent restenosis (ISR) and stent thrombosis. Intensive work to overcome the problems of ISR has successfully led to the introduction of drug-eluting stents (DES). DES has significantly reduced the rate of restenosis; it has reduced morbidity, mortality, and economic costs associated with the percutaneous treatment of coronary artery disease. Patients no longer have to come back for catheterisations due to ISR. The success of DES has shifted the focus on further developments towards enhancing long-term safety and efficacy of these devices. Bioabsorbable and polymer-free stents hold promise as successors to the current generation of DES.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hirsch AT, Gotto AM Jr (2002) Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med 7:323–331

    Article  PubMed  Google Scholar 

  2. Eggum JH, Howard SA, Goff RP, Iaizzo PA (2012) Imaging of a coronary artery stent implantation within an isolated human heart. J Cardiovasc Transl Res 5:73–74

    Article  CAS  PubMed  Google Scholar 

  3. Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ et al (2008) Postmarket evaluation of breakthrough technologies. Am Heart J 156:201–208

    Article  PubMed  Google Scholar 

  4. Martin DM, Boyle FJ (2011) Drug-eluting stents for coronary artery disease: a review. Med Eng Phys 33:148–163

    Article  PubMed  Google Scholar 

  5. Butt M, Connolly D, Lip GY (2009) Drug-eluting stents: a comprehensive appraisal. Future Cardiol 5:141–157

    Article  CAS  PubMed  Google Scholar 

  6. Alfonso F, Perez-Vizcayno MJ, Cruz A, Garcia J, Jimenez-Quevedo P, Escaned J et al (2009) Treatment of patients with in-stent restenosis. EuroIntervention 5(Suppl D):D70–D78

    PubMed  Google Scholar 

  7. Wykrzykowska JJ, Onuma Y, Serruys PW (2009) Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin Drug Deliv 6:113–126

    Article  CAS  PubMed  Google Scholar 

  8. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A et al (2008) Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359:1330–1342

    Article  CAS  PubMed  Google Scholar 

  9. Stefanadis CI (2011) Are all drug-eluting stents the same? Hellenic J Cardiol 52:96

    PubMed  Google Scholar 

  10. Akin I, Schneider H, Ince H, Kische S, Rehders TC, Chatterjee T et al (2011) Second- and third-generation drug-eluting coronary stents: progress and safety. Herz 36:190–196

    Article  CAS  PubMed  Google Scholar 

  11. Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K (2010) Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis 21:46–56

    Article  PubMed  Google Scholar 

  12. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G (2008) Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 4:31–38

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E et al (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333–342

    Article  CAS  PubMed  Google Scholar 

  14. Lange RA, Hillis LD (2010) Second-generation drug-eluting coronary stents. N Engl J Med 362:1728–1730

    Article  CAS  PubMed  Google Scholar 

  15. Lopez JJ, Keyes MJ, Nathan S, Piana R, Pencina M, Dhar G et al (2010) Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. Am Heart J 160:767–774

    Article  PubMed  Google Scholar 

  16. Kereiakes DJ, Cannon LA, Ormiston JA, Turco MA, Mann T, Mishkel GJ et al (2011) Propensity-matched patient-level comparison of the TAXUS Liberté and TAXUS element (ION) paclitaxel-eluting stents. Am J Cardiol 108:828–837

    Article  PubMed  Google Scholar 

  17. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A et al (2011) Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 7:985–994

    Article  PubMed  Google Scholar 

  18. de la Torre Hernandez JM, Windecker S (2012) Very late stent thrombosis with newer drug-eluting stents: no longer an issue? Rev Esp Cardiol (Engl Ed) 65:595–598

    Article  Google Scholar 

  19. Garg S, Serruys PW (2010) Coronary stents: looking forward. J Am Coll Cardiol 56:S43–S78

    Article  CAS  PubMed  Google Scholar 

  20. LaDisa JF, Olson LE, Hettrick DA, Warltier DC, Kersten JR, Pagel PS (2005) Axial stent strut angle influences wall shear stress after stent implantation: analysis using 3D computational fluid dynamics models of stent foreshortening. Biomed Eng Online 4:59

    Article  PubMed Central  PubMed  Google Scholar 

  21. LaDisa JF, Olson LE, Guler I, Hettrick DA, Audi SH, Kersten JR et al (2004) Stent design properties and deployment ratio influence indexes of wall shear stress: a three-dimensional computational fluid dynamics investigation within a normal artery. J Appl Physiol 97:424–430

    Article  PubMed  Google Scholar 

  22. Kolachalama VB, Tzafriri AR, Arifin DY, Edelman ER (2009) Luminal flow patterns dictate arterial drug deposition in stent-based delivery. J Control Release 133:24–30

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Pant S, Limbert G, Curzen NP, Bressloff NW (2011) Multiobjective design optimisation of coronary stents. Biomaterials 32:7755–7773

    Article  CAS  PubMed  Google Scholar 

  24. Colombo A, Stankovic G, Moses JW (2002) Selection of coronary stents. J Am Coll Cardiol 40:1021–1033

    Article  PubMed  Google Scholar 

  25. Sketch MH, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ (2005) Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol 95:8–12

    Article  CAS  PubMed  Google Scholar 

  26. Patel MJ, Patel SS, Patel NS, Patel NM (2012) Current status and future prospects of drug eluting stents for restenosis. Acta Pharm 62:473–496

    Article  CAS  PubMed  Google Scholar 

  27. Ako J, Bonneau HN, Honda Y, Fitzgerald PJ (2007) Design criteria for the ideal drug-eluting stent. Am J Cardiol 100:3M–9M

    Article  CAS  PubMed  Google Scholar 

  28. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D (2009) The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv 2:1169–1177

    Article  PubMed  Google Scholar 

  29. Puskas JE, Munoz-Robledo LG, Hoerr RA, Foley J, Schmidt SP, Evancho-Chapman M et al (2009) Drug-eluting stent coatings. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:451–462

    CAS  PubMed  Google Scholar 

  30. Mrowietz C, Franke RP, Seyfert UT, Park JW, Jung F (2005) Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clin Hemorheol Microcirc 32:89–103

    CAS  PubMed  Google Scholar 

  31. Matschke K, Tugtekin SM, Kappert U, Jung F, Park JW, Knaut M (2004) Do drug-eluting stents influence the spectrum of coronary artery bypass surgery? Herz 29:201–207

    Article  PubMed  Google Scholar 

  32. Levy Y, Mandler D, Weinberger J, Domb AJ (2009) Evaluation of drug-eluting stents’ coating durability–clinical and regulatory implications. J Biomed Mater Res B Appl Biomater 91:441–451

    Article  PubMed  Google Scholar 

  33. Parker T, Dave V, Falotico R (2011) Polymers for drug eluting stents. Curr Pharm Des 16:3978–3988

    Article  Google Scholar 

  34. Mani G, Feldman MD, Patel D, Agrawal CM (2007) Coronary stents: a materials perspective. Biomaterials 28:1689–1710

    Article  CAS  PubMed  Google Scholar 

  35. Moore JE Jr (2009) Biomechanical issues in endovascular device design. J Endovasc Ther 16(Suppl 1):I1–I11

    PubMed Central  PubMed  Google Scholar 

  36. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221–231

    Article  CAS  PubMed  Google Scholar 

  37. van der Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, van Vlijmen BJ, Quax PH et al (2005) Drug-eluting stents: results, promises and problems. Int J Cardiol 99:9–17

    Article  PubMed  Google Scholar 

  38. Deconinck E, Sohier J, De Scheerder I, Van den Mooter G (2008) Pharmaceutical aspects of drug eluting stents. J Pharm Sci 97:5047–5060

    Article  CAS  PubMed  Google Scholar 

  39. Tamburino C, Capodanno D (2009) Evolution of stents: past, present and future. Expert Rev Cardiovasc Ther 7:443–446

    Article  PubMed  Google Scholar 

  40. Burke SE, Kuntz RE, Schwartz LB (2006) Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 58:437–446

    Article  CAS  PubMed  Google Scholar 

  41. Wykrzykowska JJ, Raber L, de Vries T, Bressers M, Buszman P, Linke A et al (2009) Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. EuroIntervention 5:310–317

    Article  PubMed  Google Scholar 

  42. Grube E, Buellesfeld L (2006) BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 3:731–741

    Article  CAS  PubMed  Google Scholar 

  43. Radke PW, Weber C, Kaiser A, Schober A, Hoffmann R (2004) Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug? Curr Pharm Des 10:349–355

    Article  CAS  PubMed  Google Scholar 

  44. Pesarini G, Ferrero V, Tomai F, Paloscia L, De Cesare N, Tamburino C et al (2009) Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry. J Invasive Cardiol 21:86–91

    PubMed  Google Scholar 

  45. Pan CJ, Tang JJ, Weng YJ, Wang J, Huang N (2006) Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J Control Release 116:42–49

    Article  CAS  PubMed  Google Scholar 

  46. Grube E, Gerckens U, Muller R, Bullesfeld L (2002) Drug eluting stents: initial experiences. Z Kardiol 91(Suppl 3):44–48

    Article  CAS  PubMed  Google Scholar 

  47. Yang J, Zeng Y, Zhang C, Chen YX, Yang Z, Li Y et al (2013) The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials 34:1635–1643

    Article  CAS  PubMed  Google Scholar 

  48. Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ (1999) Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Control Release 60:129–142

    Article  CAS  PubMed  Google Scholar 

  49. Kavanagh CA, Rochev YA, Gallagher WM, Dawson KA, Keenan AK (2004) Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Ther 102:1–15

    Article  CAS  PubMed  Google Scholar 

  50. Vorpahl M, Virmani R, Ladich E, Finn AV (2009) Vascular remodeling after coronary stent implantation. Minerva Cardioangiol 57:621–628

    CAS  PubMed  Google Scholar 

  51. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW et al (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352–356

    Article  PubMed  Google Scholar 

  52. Jeremias A, Kirtane A (2008) Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 148:234–238

    Article  PubMed  Google Scholar 

  53. Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Maldonado G et al (2009) 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv 2:422–427

    Article  PubMed  Google Scholar 

  54. Curcio A, Torella D, Cuda G, Coppola C, Faniello MC, Achille F et al (2004) Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am J Physiol Heart Circ Physiol 286:H902–H908

    Article  CAS  PubMed  Google Scholar 

  55. Schoenkerman AB, Lundstrom RJ (2009) Coronary stent infections: a case series. Catheter Cardiovasc Interv 73:74–76

    Article  PubMed  Google Scholar 

  56. de Belder MA (2008) NICE guidelines for the use of drug-eluting stents: how do we establish worth? Heart 94:1646–1648

    Article  PubMed  Google Scholar 

  57. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555

    Article  PubMed  Google Scholar 

  58. Kereiakes DJ (2010) Safety of drug-eluting stents. Rev Cardiovasc Med 11:187–199, quiz 200

    PubMed  Google Scholar 

  59. Webster MW, Ormiston JA (2007) Drug-eluting stents and late stent thrombosis. Lancet 370:914–915

    Article  PubMed  Google Scholar 

  60. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C et al (2010) Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 3:174–183

    Article  CAS  PubMed  Google Scholar 

  61. Levi Y, Domb AJ, Amir N, Eliyahu N, Cohn U, Tal N. Crystalline drug-containing coatings. WO2010086863 A3, pp 1–55

    Google Scholar 

  62. Khan W, Farah S, Domb AJ (2012) Drug eluting stents: developments and current status. J Control Release 161:703–712

    Article  CAS  PubMed  Google Scholar 

  63. Levy Y, Khan W, Farah S, Domb AJ (2012) Surface crystallization of rapamycin on stents using a temperature induced process. Langmuir 28:6207–6210

    Article  CAS  PubMed  Google Scholar 

  64. Abizaid A, Costa JR Jr (2010) New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 3:384–393

    Article  CAS  PubMed  Google Scholar 

  65. Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Mattos LA et al (2008) Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. JACC Cardiovasc Interv 1:545–551

    Article  PubMed  Google Scholar 

  66. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al (2006) Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113:273–279

    Article  CAS  PubMed  Google Scholar 

  67. Di Mario C, Ferrante G (2008) Biodegradable drug-eluting stents: promises and pitfalls. Lancet 371:873–874

    Article  PubMed  Google Scholar 

  68. Ramcharitar S, Serruys PW (2008) Fully biodegradable coronary stents: progress to date. Am J Cardiovasc Drugs 8:305–314

    Article  CAS  PubMed  Google Scholar 

  69. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369:1869–1875

    Article  CAS  PubMed  Google Scholar 

  70. Erbel R, Bose D, Haude M, Kordish I, Churzidze S, Malyar N et al (2007) Absorbable coronary stents. New promising technology. Herz 32:308–319

    Article  PubMed  Google Scholar 

  71. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S et al (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404

    Article  CAS  PubMed  Google Scholar 

  72. Ormiston JA, Serruys PW (2009) Bioabsorbable coronary stents. Circ Cardiovasc Interv 2:255–260

    Article  CAS  PubMed  Google Scholar 

  73. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899–907

    Article  CAS  PubMed  Google Scholar 

  74. Garg S, Serruys P (2009) Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol 57:537–565

    CAS  PubMed  Google Scholar 

  75. Park K (2012) Dual drug-eluting stent. J Control Release 159:1

    Article  CAS  PubMed  Google Scholar 

  76. Song SJ, Kim KS, Park YJ, Jeong MH, Ko YM, Cho DL (2009) Preparation of a dual-drug-eluting stent by grafting of ALA with abciximab on a bare metal stent. J Mater Chem 19:8135–8141

    Article  CAS  Google Scholar 

  77. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M et al (2009) A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 30:923–931

    Article  CAS  PubMed  Google Scholar 

  78. Ma X, Oyamada S, Gao F, Wu T, Robich MP, Wu H et al (2011) Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. J Pharm Biomed Anal 54:807–811

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Kleinedler JJ, Foley JD, Orchard EA, Dugas TR (2012) Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. J Control Release 159:27–33

    Article  CAS  PubMed  Google Scholar 

  80. Kukreja N, Onuma Y, Daemen J, Serruys PW (2008) The future of drug-eluting stents. Pharmacol Res 57:171–180

    Article  CAS  PubMed  Google Scholar 

  81. Variola F, Vetrone F, Richert L, Jedrzejowski P, Yi JH, Zalzal S et al (2009) Improving biocompatibility of implantable metals by nanoscale modification of surfaces: an overview of strategies, fabrication methods, and challenges. Small 5:996–1006

    Article  CAS  PubMed  Google Scholar 

  82. Youssefian S, Rahbar N (2013) Nano-scale adhesion in multilayered drug eluting stents. J Mech Behav Biomed Mater 18:1–11

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India

    Wahid Khan & Rajesh Thipparaboina

  2. Faculty of Medicine, Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel

    Shady Farah & Abraham J. Domb

  3. Cardiovascular Division, Department of Medicine, Columbia University, New York, NY, USA

    Judah Z. Weinberger

Authors
  1. Wahid Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajesh Thipparaboina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shady Farah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Judah Z. Weinberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abraham J. Domb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abraham J. Domb .

Editor information

Editors and Affiliations

  1. School of Pharmacy-Faculty of Medicine The Hebrew University of Jerusalem, Jerusalem, Israel

    Abraham J. Domb

  2. Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh, India

    Wahid Khan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Controlled Release Society

About this chapter

Cite this chapter

Khan, W., Thipparaboina, R., Farah, S., Weinberger, J.Z., Domb, A.J. (2014). Drug-Eluting Stents. In: Domb, A., Khan, W. (eds) Focal Controlled Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9434-8_18

Download citation

Publish with us

Policies and ethics

Search

Navigation